Monte Rosa Therapeutics (NASDAQ:GLUE) Downgraded by Zacks Investment Research to Sell

Monte Rosa Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Monte Rosa Therapeutics Downgraded by Zacks Investment Research on 10-12-21. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

View More Monte Rosa Therapeutics (NASDAQ:GLUE) Downgraded by Zacks Investment Research to Sell

Reports Strong First-Quarter Financial Results Monte Rosa Therapeutics (NASDAQ:GLUE)

Earnings results for Monte Rosa Therapeutics , Analyst Opinion on Monte Rosa Therapeutics , Earnings and Valuation of (NASDAQ:GLUE), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Reports Strong First-Quarter Financial Results Monte Rosa Therapeutics (NASDAQ:GLUE)